Pliant Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of November 9, 2026, the company had 61,990,635 shares of common stock, $0.0001 par value per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Clinical program: The filing references an ongoing Phase 1a/1b open-label, dose escalation and indication expansion trial of PLN-101095.
  • Regulatory designation: The filing references Fast Track designation of PLN-101095 in combination with pembrolizumab for the treatment of immune checkpoint inhibitor (ICI)-refractory tumors.
  • Going concern risk noted: The company disclosed that it "will require substantial additional capital to finance our operations" and has "incurred significant net losses since inception."

Pliant Therapeutics Discloses Financial Position and Clinical Program Status for September 30, 2026 Quarter

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a Delaware-incorporated biopharmaceutical company headquartered at 331 Oyster Point Blvd., South San Francisco, CA 94080, filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The filing was submitted November 12, 2026, with Commission File Number 001-39303. As of November 9, 2026, the registrant reported 61,990,635 shares of common stock outstanding at a par value of $0.0001 per share.

According to the filing, the company is not an emerging growth company and indicated it is not a shell company. The report covers standard quarterly disclosures including condensed financial statements, management's discussion and analysis, and risk factors. Among the risks summarized, the company disclosed that it "has incurred significant net losses since inception" and expects "to continue to incur significant net losses for the foreseeable future," and that additional capital will be required to finance ongoing operations.

The filing identifies PLN-101095 as the company's lead clinical-stage asset, currently in a Phase 1a/1b open-label, dose escalation and indication expansion trial. The company also references Fast Track designation for PLN-101095 in combination with pembrolizumab for treatment of ICI-refractory tumors. The report contains forward-looking statements, which the filing notes are subject to risks and uncertainties described in its Risk Factors section, and the company stated it undertakes no obligation to update those statements except as required by law.

What Was Disclosed

Pliant Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 61,990,635 shares outstanding as of November 9, 2026, its non-accelerated and smaller reporting company status, and ongoing clinical development of PLN-101095.